New Trump tariffs on pharmaceuticals could double the cost of common prescription drugs, raising prices for medications like ...

As blockbuster heart failure drug Entresto inches toward a patent cliff, Novartis is calling on the FDA—again—to keep early-bird generics at bay. At the time, Novartis argued greenlighting any generic ...

Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as a ...

If you’re looking at treatment options for heart failure, you may want to learn more about Entresto (sacubitril/valsartan). It’s a prescription drug used to treat ...

Entresto (sacubitril/valsartan) has interactions with alcohol, other medications, and some supplements. For example, Entresto can interact with potassium supplements ...

Entresto (sacubitril/valsartan) is a brand-name drug prescribed to treat heart failure. Entresto has interactions with some other drugs and certain supplements ...

Entresto is a brand-name prescription medication containing sacubitril and valsartan. The FDA approved generic versions of Entresto in May 2024, and the drug was launched in July 2025. According to ...

After Eli Lilly and Boehringer Ingelheim posted a landmark win for their diabetes drug Jardiance in heart failure patients with preserved ejection fraction earlier this month, the pressure is ...

Novartis AG NVS announced results from a post-hoc analysis from the PARADIGM-HF trial on cardiovascular drug Entresto. The results were published in JAMA Cardiology. The results demonstrated that ...

Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs that will be subject to Medicare pricing negotiations, claiming that the move will ...

Best practice around value-based contracting, which involves tying reimbursement for drugs (or devices or digital health tools, etc.) to proof that they deliver improved outcomes or lower treatment ...

Novartis' drug, which combines sacubitril and valsartan, is the first to directly treat patients with heart failure with preserved ejection fraction. FDA on Tuesday granted Entresto, a combination of ...